Mast Therapeutics, Inc. (MSTX)

[biopharm]

"Culley says that the drug hasn’t yet demonstrated its full capabilities, and an upcoming Phase III trial at ADVENTRX, expected to initiate by year’s-end, will improve on older testing strategies. Discussing the development history of ANX-188, he says, “It was very interesting to us to see that in a study that was underpowered and really not optimally designed, they still very nearly reached the threshold of success which is needed for FDA approval.” With better financial backing and advanced manufacturing methods, Culley believes ANX-188 will move to the market with a strong IP portfolio to protect it. The only FDA approved drug for treating Sickle Cell Anemia, hydroxyurea, is sold by Bristol-Myers Squibb (NYSE:BMY) as Hydrea and Droxia.

The discussion touches on the company’s other pipeline products and ADVENTRX’s financial position. Culley also discusses expanding indications for ANX-188, and explains how recent hires at the company bring valuable clinical and regulatory expertise to this development-stage biotech."

http://propthink.com/propthink-interviews-adventrx-pharmaceuticals/2353